This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Westerhof, G. R. Articles by Down, J. D. Search for Related Content PubMed PubMed Citation Articles by Westerhof, G. R. Articles by Down, J. D.

Comparison of Different Busulfan Analogues for Depletion of Hematopoietic Stem Cells and Promotion of Donor-Type Chimerism in Murine Bone Marrow Transplant Recipients¹

Department of Hematology, Erasmus University, 3000 DR Rotterdam, the Netherlands [G. R. W., R. E. P., A. B., I. B.]; Groningen Institute for Drug Studies, University of Groningen, 9713 AV Groningen, the Netherlands [J. H. D., J. D. D.]; and Drug Development Group, Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester M20 4BX, United Kingdom [A. T. M., J. A. H., M. J. D.]

Busulfan (1,4-butanediol dimethanesulfonate, BU) is relatively unique among other standard chemotherapy compounds in its ability to deplete noncycling primitive stem cells in the host and consequently to allow for high levels of long-term, donor-type engraftment after bone marrow transplantation (BMT). Such a property explains why this drug can be used as an alternative to total body irradiation in preparative regimes for BMT. However, as with radiation, BU conditioning is still troubled by severe toxicities that limit its applications to suboptimal drug doses. These problems stress the need for other BMT-conditioning drugs that are better tolerated and more selectively targeted toward normal and malignant hematopoietic stem cells. We have therefore compared the effects of various novel dimethanesulfonate compounds (related to BU) in terms of their toxicity to different stem cell subsets in vivo and in vitro and their ability to provide for long-term donor bone marrow engraftment using the congenic glucose-6-phosphate isomerase type 1 marker. Introduction of a benzene or cyclohexane ring in some of these drugs affords rigidity to the molecule and restricts the spatial positioning of the alkylating groups. Among 25 different compounds thus far tested at single doses, PL63 [cis-1,2-(2-hydroxyethyl) cyclohexane dimethanesulfonate] proved to be the most effective in providing for hematopoietic engraftment. The trans-isomer of the same compound gave significantly less engraftment and was comparable with the effects of dimethylbusulfan and Hepsulfam. The engraftment data correlated well with the depletion of different bone marrow stem cell subsets in the host as measured using the cobblestone area forming cell assay. The extent of stem cell depletion could not be explained on the basis of the distance and orientation of the two alkylating groups. Pharmacokinetic data, however, indicate that there is a correlation between biological activity and plasma levels reached.

The diverse cytotoxic effects shown by these novel analogues of BU have provided a basis for relating biological activity with pharmacokinetic properties rather than with structural properties such as distance and orientation of the two alkylating groups. The identification of highly active compounds such as PL63 offers an opportunity for further developing other closely related drugs for potential application in clinical BMT conditioning therapy.

This article has been cited by other articles:

				A. Gutierrez-Fernandez, M. Inada, M. Balbin, A. Fueyo, A. S. Pitiot, A. Astudillo, K. Hirose, M. Hirata, S. D. Shapiro, A. Noel, et al. Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8) FASEB J, August 1, 2007; 21(10): 2580 - 2591. [Abstract] [Full Text] [PDF]

				J. Casper, W. Knauf, T. Kiefer, D. Wolff, B. Steiner, U. Hammer, R. Wegener, H.-D. Kleine, S. Wilhelm, A. Knopp, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation Blood, January 15, 2004; 103(2): 725 - 731. [Abstract] [Full Text] [PDF]

				G. Andersson, B. M. W. Illigens, K. W. Johnson, D. Calderhead, C. LeGuern, G. Benichou, M. E. White-Scharf, and J. D. Down Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice Blood, June 1, 2003; 101(11): 4305 - 4312. [Abstract] [Full Text] [PDF]

				J. D. Down and M. E. White-Scharf Reprogramming Immune Responses: Enabling Cellular Therapies and Regenerative Medicine Stem Cells, January 1, 2003; 21(1): 21 - 32. [Abstract] [Full Text] [PDF]